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Exacerbations of COPD are the largest single cause of hospital admission with 
respiratory disease, and are frequently associated with impaired gas exchange and 
mortality rates of up to 14%.1 Acute hypercapnic respiratory failure leads to admis-
sions to intensive care units with a mortality rate of 59% at one year.2
Noninvasive ventilation (NIV) is a well established and validated therapy for 
acidotic hypercapnia respiratory failure in COPD,1 a leading cause of global mortality 
and morbidity. The use of NIV in patients with acute type II or chronic respiratory 
failure has increased over the past 10 years.
A Cochrane Systematic Review determined the efficacy of NIV in the management 
of patients with respiratory failure due to an acute exacerbation of COPD. NIV resulted 
in decreased mortality, decreased need for intubation, and a reduction in treatment 
failure.1 However a Royal College of Physicians/British Thoracic Society (RCP/BTS) 
audit failed to provide evidence that NIV was effective in reducing mortality. The 
reason for their finding is unclear.3
There is little convincing evidence for the use of NIV in severe, but stable COPD. 
In many cases, patients with severe chronic COPD may not tolerate long-term NIV. 
However, NIV has been accepted as the convention for ventilation support for patients 
who have developed progressive type II respiratory failure.4
What is less clear, however, is the quality of how NIV is delivered to patients in 
hospitals in the UK.
The RCP/BTS audit of NIV use in 233 hospitals showed NIV was available in 
all but 11 hospitals, but only 31% of patients who were admitted with hypercapnic 
acidotic exacerbations of COPD (pH  7.35) received NIV.3
A recent update of the guidelines of NIV has reinforced much of current practice 
but thrown up several interesting questions.5
Data from the recent BTS National COPD audit (NCROP) demonstrated large 
gaps in training of staff, provision of written guidelines and the ability to audit 
practice.6
Any patient on NIV is classified as receiving Critical Level 2 care, defined as 
“Patients requiring more detailed observation or intervention including support for a 
single failed organ system”. This suggests NIV should be administered in an inten-
sive care unit (ICU) or high dependency unit (HDU) setting, but it has been widely 
recognised that NIV can be successfully used outside the ICU or HDU.International Journal of COPD 2010:5
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In the UK previous studies have shown that 40% of NIV 
is performed on general medical/respiratory wards, 12% by 
HDUs and 13% by ICU.2
We conducted a prospective review of  NIV practice at our 
hospital in order to compare local practice against guideline 
stated best practice. In this review, conducted over one year, 
we noted that 64% of patients were started on NIV in the acci-
dent and emergency department. The new guidelines suggest 
that a dedicated area of high-dependency care is needed with 
appropriately trained staff. Certainly most emergency depart-
ments have this, but efforts need to be made to ensure training 
is adequate and that staff keeps up to date.
Concerns have been raised about the use of NIV in situa-
tions other than hypercapnic respiratory failure in the context 
of COPD. Technological advances have made the technique 
relatively simple and thus we are concerned that NIV is being 
inappropriately used, most often in the wrong indication. 
This may result in serious negative clinical consequences. 
In our review of local practice, we found 55% of patients 
were receiving NIV for either heart failure or pneumonia, 
neither of which are indications for use of NIV in the BTS 
guidelines.5
In the RCP survey, of the 1095 patients who were not 
commenced on NIV despite fulfilling criteria, the reasons 
for not starting NIV included “inappropriate” in 321, “no 
facilities” in 48, “patient refused” in 13, “treatment failed” 
in 3, with no reason offered in 710.3
A review of NIV use in patients with acute cardiogenic 
pulmonary edema showed a significant reduction in the 
mortality rate by nearly 45% compared with conventional 
therapy. There was also a significant decrease in the “need to 
intubate” rate. However, continuous positive airway pressure 
or bilevel positive airway pressure showed no differences 
in intubation or mortality rates in the analysis of studies 
comparing the two techniques.7
The new guidelines recommend that efforts must be 
now made to comment on gaining the patient’s consent and 
document the reasoning for the use of NIV. From a patient’s 
perspective, more compliance would be gained if the patient 
felt they had some control of the process and if a variety of 
interfaces were tried. But in a busy emergency department, 
these are often not feasible. We found poor documentation 
on patient’s consent to treatment and also almost one in 
seven had no documentation of why NIV was instituted.
The new guidelines also state that at least a second year 
speciality trainee (ST2) must make the decision on the com-
mencement of NIV, but we found that in 25% of cases this was 
not the case. This is especially difficult in most emergency 
units as they are often staffed by a mixture of nonspecialist 
junior and middle-grade trainees.
NIV is a very well validated and successful treatment 
when used for the right indication, with the correctly trained 
staff and with motivated patients. At present we believe 
that there are problems common to many emergency and 
respiratory departments which urgently need addressing.
Solutions need to be designed and implemented by local 
teams. They might include a dedicated NIV team, able to 
provide 24/7 care. This is, however, only feasible in large units 
with many trained staff. For smaller units lead staff should be 
trained regularly to maintain knowledge and competencies 
for this important intervention, which is most often utilized 
in the period termed “out-of hours”.
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